NovaSeq X And SomaLogic Will Drive Precision Medicine Despite Challenges

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 22 Analysts
Published
13 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$157.43
40.0% undervalued intrinsic discount
06 Aug
US$94.43
Loading
1Y
-22.0%
7D
-11.5%

Author's Valuation

US$157.4

40.0% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 8.24%

Shared on30 Apr 25
Fair value Decreased 2.24%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget has increased future PE multiple from 30.5x to 36.5x.

Shared on16 Apr 25
Fair value Increased 0.19%

AnalystHighTarget made no meaningful changes to valuation assumptions.